As of November 6, 2026, Arrowhead Pharmaceuticals, Inc. is a publicly traded company (Nasdaq: ARWR); its largest reported holder is BlackRock, with 10.1% on Schedule 13G/A of July 27, 2026, then Avoro Capital Advisors LLC (9.64%). The largest insider holding is Anzalone Christopher Richard, the chief executive and a director, with 3,792,739 shares (2.7% of shares outstanding), per Form 4 of January 5, 2026 (Schedule 13G/A, July 27, 2026).
Is this your company?
About to sign with, pay or invest in Arrowhead Pharmaceuticals, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Arrowhead Pharmaceuticals, Inc. a real, registered company?
- Arrowhead Pharmaceuticals Inc files with the SEC under CIK 879407 (its SEC filings).
- Its shares are listed under the ticker ARWR on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Pasadena, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under ARROWHEAD PHARMACEUTICALS INC in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Matt Cohen, Director (Form 8-K filed 2026-06-16). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Fidelity (FMR) (filed 2026-11-05).
Who are Arrowhead Pharmaceuticals, Inc.'s owners and officers?
Arrowhead Pharmaceuticals, Inc.: incorporated in Delaware; business address in Pasadena, California; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-11-05).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-05 | Fmr LLC | 6.6% |
| Schedule 13G/A, 2026-08-14 | Avoro Capital Advisors LLC | 9.64% |
| Schedule 13G/A, 2026-07-31 | Vanguard Portfolio Management | 4.53% |
| Schedule 13G/A, 2026-07-27 | Blackrock, Inc. | 10.1% |
| Schedule 13G, 2026-05-06 | Fmr LLC | 5.2% |
| Schedule 13G, 2026-04-29 | Vanguard Capital Management | 5.05% |
| Schedule 13G, 2026-04-28 | Vanguard Portfolio Management | 5.19% |
| Schedule 13G/A, 2026-04-24 | Blackrock, Inc. | 12.2% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-01-21 | Blackrock, Inc. | 15% |
| Schedule 13D/A, 2025-08-15 | Sarepta Therapeutics, Inc. | 0% |
| Schedule 13G/A, 2025-08-14 | Avoro Capital Advisors LLC | 8.3% |
Questions about who owns Arrowhead Pharmaceuticals, Inc.
Who owns Arrowhead Pharmaceuticals, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Arrowhead Pharmaceuticals, Inc.: Blackrock, Inc. (10.1%, Schedule 13G/A, filed 2026-07-27), Avoro Capital Advisors LLC (9.64%, Schedule 13G/A, filed 2026-08-14), Fmr LLC (6.6%, Schedule 13G/A, filed 2026-11-05) and Vanguard Capital Management (5.05%, Schedule 13G, filed 2026-04-29).
Who are the largest shareholders of Arrowhead Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of Arrowhead Pharmaceuticals, Inc. on this page are Blackrock, Inc. (10.1%), Avoro Capital Advisors LLC (9.64%) and Fmr LLC (6.6%).
When did Blackrock, Inc. buy into Arrowhead Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Blackrock, Inc. on this page is the Schedule 13G/A, filed 2026-01-21, reporting 15%; its latest, Schedule 13G/A filed 2026-07-27, reports 10.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Arrowhead Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Arrowhead Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Arrowhead Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-06-16 | Matt Cohen | Director | appointed | 2026-06-12 |
Which insiders own Arrowhead Pharmaceuticals, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 3,792,739 shares (2.7% of shares outstanding) (Form 4, 2026-01-05).
- , the chief operating officer: 547,408 shares (0.39% of shares outstanding) (Form 4, 2026-01-08).
- , the chief financial officer: 455,433 shares (0.32% of shares outstanding) (Form 4, 2025-01-07).
- , the chief medical officer: 226,958 shares (0.16% of shares outstanding) (Form 4, 2026-04-24).
- , the chief financial officer: 162,905 shares (0.12% of shares outstanding) (Form 4, 2026-04-24).
Shares outstanding: 141,254,467 as of 2026-07-30, from the company's latest SEC cover page.
How much has Arrowhead Pharmaceuticals, Inc. raised?
No fundraising or offering filing from Arrowhead Pharmaceuticals, Inc. is on file with us.
Keep reading
More on Arrowhead Pharmaceuticals, Inc. and the records around it.
Arrowhead Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Leadership changes Jun 2026
Companies that share a holder
- Avoro Capital Advisors LLC also filed stake reports on 18 other companies: Avalo Therapeutics, Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026), Scribe Therapeutics, Inc. (Jul 2026)
- STATE STREET CORPORATION also filed stake reports on 343 other companies: TRADE DESK INC/THE (Oct 2026), CENTRUS ENERGY CORP (Sep 2026), ACADIA PHARMACEUTICALS INC (Aug 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/arrowhead-pharmaceuticals